In our study, serum levels of AIM were tended to be correlated with HOMA-IR, although this correlation was not significant and AIM levels were not associated with the Matsuda index of whole-body insulin sensitivity [ 19].
Serum levels of AIM tended to be correlated with HOMA-IR, but this association did not show statistical significance.
In these 39 patients, there was no significant association between serum levels of AIM and adiponectin, leptin, or resistin.
In addition, serum levels of adiponectin, leptin, and resistin were significantly associated with WBISI, but serum levels of AIM were not correlated with WBISI.
The relationship between serum levels of AIM or adipokines and the severity of histological features including hepatic steatosis and inflammation were assessed in CHC patients.
In addition, we determined whether serum levels of AIM and adipocytokines are associated with IR or sensitivity in patients with CHC.
In this study, we analyzed the association between serum levels of AIM, leptin, adiponectin, and resistin, and clarified the clinical significance of serum AIM levels in patients with CHC.
In contrast, serum levels of AIM may not be correlated with IR as assessed by HOMA-IR, but adipocytokines were associated with IR and insulin sensitivity, and serum levels of leptin were associated with hepatic steatosis.
We then determined whether serum levels of AIM are associated with histological features such as the degree of hepatic steatosis and hepatic inflammation and the stage of hepatic fibrosis.
Recently, it has been reported that an increase in the blood levels of AIM is a critical event in the initiation of macrophage recruitment into adipose tissue, which is followed by IR [ 8].
